Acute Congestive Heart FailureHeart Failure With Reduced Ejection FractionHeart Failure With Normal Ejection Fraction
Investigational drug(s) / intervention(s)
Cardiac MRI
Cardiac MRI: Cardiac MRI is a test that allows us to look at how the heart muscle works and the amount of scar tissue in your heart. Screening questions will be asked to make sure that patients are not pregnant, and that they have kidney function tests to confirm that IV contrast used (gadolinium) during the MRI is safe for them.
Study summary
The purpose of this American Heart Association-funded and NIH-funded study is to examine circulating RNAs in the acute CHF setting, how they change with decongestive therapy, and their function in vitro and in vivo.
The investigators are testing the hypothesis that ex-RNA levels change significantly during decongestion therapy and can be used as a marker of those individuals who respond to CHF therapy (in terms of cardiac structure or outcome). Additionally, the translational research design allows the investigators to assay the effects of these RNAs on tissue phenotypes in vitro.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Age \>/= 18 years of age
2. Assessment of LV function within the last year or planned during hospital admission
3. Acute CHF diagnosis, requiring clinical signs and/or symptoms (including exertional or rest dyspnea, orthopnea or PND) AND
1. N-terminal pro-BNP level \> 1000 pg/ml or BNP \> 400 pg/ml, OR
2. Clinical evidence of congestion:
* X-ray evidence of pulmonary edema or pleural effusions
* Elevated JVP, lower extremity edema, or rales on pulmonary examination
* Right heart catheterization evidence of elevated filling pressures (RA pressure \> 10 mmHg; PCWP \> 18 mmHg)
4. Clinical response to IV diuretic therapy (as judged by a physician)
Exclusion Criteria:
1. Hematocrit at time of consent \< 30%
2. End-stage non-cardiovascular diseases
1. Known HIV/AIDS
2. Cirrhosis
3. Hemodialysis-dependent renal failure
3. Pregnancy (as adjudicated by patient history)
4. Ventricular assist device support
5. Acute mechanical support on admission
6. Post-heart transplant
7. Malignancy within the last 1 year or clinically active rheumatologic or autoimmune illnesses
Primary outcome measure(s)
Plasma RNAs levels (rpm by RNAseq) in patients with acute CHF — admission vs. decongestion (up to 2 weeks) Identification of plasma RNAs (absolute reads per million) by RNA sequencing in 1 ml of plasma that are greater than 2 fold increased with p value \< 0.05.
Trial sites (3)
Facility
City
Region
Status
Massachusetts General Hospital
Boston
Massachusetts
Brigham and Women's Hospital
Boston
Massachusetts
Beth Israel Deaconess Medical Center
Boston
Massachusetts
More Massachusetts General Hospital trials in Israel
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
